Letter to the editor: “No benefit of concomitant immunomodulator therapy on efficacy of biologics that are not tumor necrosis factor antagonists in patients with inflammatory bowel diseases: a meta-analysis”

Tumor Necrosis ◽

Meta Analysis ◽

Letter To The Editor ◽

Bowel Diseases ◽

Inflammatory Bowel ◽

P154 PRIMARY NON-RESPONSE TO TUMOR NECROSIS FACTOR ANTAGONISTS IS ASSOCIATED WITH INFERIOR RESPONSE TO SECOND-LINE BIOLOGICS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES: A SYSTEMATIC REVIEW AND META-ANALYSIS

Gastroenterology ◽

10.1053/j.gastro.2017.11.204 ◽

2018 ◽

Vol 154 (1) ◽

pp. S81-S82

Author(s):

Siddharth Singh ◽

John George ◽

Brigid S. Boland ◽

Niels Vande Casteele ◽

William J. Sandborn

Keyword(s):

Systematic Review ◽

Tumor Necrosis Factor ◽

Tumor Necrosis ◽

Meta Analysis ◽

Second Line ◽

Bowel Diseases ◽

Inflammatory Bowel ◽

P154 PRIMARY NON-RESPONSE TO TUMOR NECROSIS FACTOR ANTAGONISTS IS ASSOCIATED WITH INFERIOR RESPONSE TO SECOND-LINE BIOLOGICS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES: A SYSTEMATIC REVIEW AND META-ANALYSIS

10.1093/ibd/izy037.025 ◽

2018 ◽

Vol 24 (suppl_1) ◽

pp. S57-S57

Author(s):

Siddharth Singh ◽

John George ◽

Brigid S Boland ◽

Niels Vande Casteele ◽

William J Sandborn

Keyword(s):

Systematic Review ◽

Tumor Necrosis Factor ◽

Tumor Necrosis ◽

Meta Analysis ◽

Second Line ◽

Bowel Diseases ◽

Inflammatory Bowel ◽

Faculty Opinions recommendation of Primary Non-Response to Tumor Necrosis Factor Antagonists is Associated with Inferior Response to Second-line Biologics in Patients with Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.732568747.793569688 ◽

2020 ◽

Author(s):

Jack Satsangi

Keyword(s):

Systematic Review ◽

Tumor Necrosis Factor ◽

Tumor Necrosis ◽

Meta Analysis ◽

Second Line ◽

Bowel Diseases ◽

Inflammatory Bowel ◽

No Benefit of Concomitant Immunomodulator Therapy on Efficacy of Biologics That Are Not Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Diseases: A Meta-Analysis

Clinical Gastroenterology and Hepatology ◽

10.1016/j.cgh.2020.06.071 ◽

2020 ◽

Cited By ~ 1

Author(s):

Clara Yzet ◽

Momar Diouf ◽

Siddarth Singh ◽

Franck Brazier ◽

Justine Turpin ◽

...

Keyword(s):

Tumor Necrosis Factor ◽

Tumor Necrosis ◽

Meta Analysis ◽

Bowel Diseases ◽

Inflammatory Bowel ◽

Faculty Opinions recommendation of Primary Non-Response to Tumor Necrosis Factor Antagonists is Associated with Inferior Response to Second-line Biologics in Patients with Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.732568747.793573425 ◽

2020 ◽

Author(s):

Gwo-Tzer Ho ◽

Rahul Kalla

Keyword(s):

Systematic Review ◽

Tumor Necrosis Factor ◽

Tumor Necrosis ◽

Meta Analysis ◽

Second Line ◽

Bowel Diseases ◽

Inflammatory Bowel ◽

Metabolic Functions of Gut Microbes Associate With Efficacy of Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Diseases

Gastroenterology ◽

10.1053/j.gastro.2019.07.025 ◽

2019 ◽

Vol 157 (5) ◽

pp. 1279-1292.e11 ◽

Cited By ~ 40

Author(s):

Konrad Aden ◽

Ateequr Rehman ◽

Silvio Waschina ◽

Wei-Hung Pan ◽

Alesia Walker ◽

...

Keyword(s):

Tumor Necrosis Factor ◽

Tumor Necrosis ◽

Gut Microbes ◽

Metabolic Functions ◽

Bowel Diseases ◽

Inflammatory Bowel ◽

Relationship between the polymorphism of tumor necrosis factor-α-308 G>A and susceptibility to inflammatory bowel diseases and colorectal cancer: a meta-analysis

European Journal of Human Genetics ◽

10.1038/ejhg.2010.159 ◽

2011 ◽

Vol 19 (4) ◽

pp. 432-437 ◽

Cited By ~ 30

Author(s):

Wang Fan ◽

Wang Maoqing ◽

Chen Wangyang ◽

Hu Fulan ◽

Li Dandan ◽

...

Keyword(s):

Colorectal Cancer ◽

Tumor Necrosis Factor ◽

Tumor Necrosis ◽

Tumor Necrosis Factor Α ◽

Meta Analysis ◽

Bowel Diseases ◽

Inflammatory Bowel ◽

Factor Α ◽

Faculty Opinions recommendation of Metabolic Functions of Gut Microbes Associate With Efficacy of Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Diseases.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.736230436.793579095 ◽

2020 ◽

Author(s):

Eduard Stange

Keyword(s):

Tumor Necrosis Factor ◽

Tumor Necrosis ◽

Gut Microbes ◽

Metabolic Functions ◽

Bowel Diseases ◽

Inflammatory Bowel ◽

Listeria monocytogenes infection in patients with inflammatory bowel diseases receiving anti-tumor necrosis factor therapy

Revista Española de Enfermedades Digestivas ◽

10.4321/s1130-01082010001000014 ◽

2010 ◽

Vol 102 (10) ◽

Cited By ~ 9

Author(s):

J. M. Ramos ◽

M. F. García-Sepulcre ◽

M. Masiá ◽

A. Brotons ◽

M. C. Grau ◽

...

Keyword(s):

Listeria Monocytogenes ◽

Tumor Necrosis Factor ◽

Tumor Necrosis ◽

Listeria Monocytogenes Infection ◽

Bowel Diseases ◽

Factor Therapy ◽

Inflammatory Bowel ◽

S0861 Comparative Risk of Serious Infections With Tumor Necrosis Factor-α Antagonists vs Vedolizumab in Patients With Inflammatory Bowel Diseases

The American Journal of Gastroenterology ◽

10.14309/01.ajg.0000705492.87799.ce ◽

2020 ◽

Vol 115 (1) ◽

pp. S444-S445

Author(s):

Siddharth Singh ◽

Herbert Heien ◽

Jeph Herrin ◽

Parambir S. Dulai ◽

Lindsey Sangaralingham ◽

...

Keyword(s):

Tumor Necrosis Factor ◽

Tumor Necrosis ◽

Tumor Necrosis Factor Α ◽

Serious Infections ◽

Bowel Diseases ◽

Comparative Risk ◽

Inflammatory Bowel ◽

Factor Α ◽